180P Real-world outcomes of patients with hepatocellular carcinoma receiving first-line atezolizumab with bevacizumab: A UK Midlands cohort

The IMbrave150 trial established atezolizumab plus bevacizumab (ATE/BEV) as a first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC), demonstrating improved overall survival (OS) and progression-free survival (PFS) over sorafenib. Ongoing real-world data collection are needed to assess ATE/BEV effectiveness and safety.

Authors

Institutions

Publication Details

Journal
Immuno-Oncology Technology
Published
2025-12-01
DOI
https://doi.org/10.1016/j.iotech.2025.101263
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

180P Real-world outcomes of patients with hepatocellular carcinoma receiving first-line atezolizumab with bevacizumab: A UK Midlands cohort

S. Hussain, B. Greef, A.A. Suwaidan, H.E.M. Daniels et al.
Immuno-Oncology Technology
Hepatocellular Carcinoma Treatment and Prognosis
article

180P Real-world outcomes of patients with hepatocellular carcinoma receiving first-line atezolizumab with bevacizumab: A UK Midlands cohort

S. Hussain, B. Greef, A.A. Suwaidan, H.E.M. Daniels, M. Quinlan, K. Maru, J. Hancock, S. Dulloo, S. Sivakumar, R. Phillips
article en

Abstract

The IMbrave150 trial established atezolizumab plus bevacizumab (ATE/BEV) as a first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC), demonstrating improved overall survival (OS) and progression-free survival (PFS) over sorafenib. Ongoing real-world data collection are needed to assess ATE/BEV effectiveness and safety.

Immuno-Oncology TechnologyVol. 28
University Hospitals Birmingham NHS Foundation Trust (GB), Nottingham University Hospitals NHS Trust (GB), University of Nottingham (GB), University of Leicester (GB), Nottingham General Hospital (GB), University Hospitals of Leicester NHS Trust (GB), Nottingham City Hospital (GB), NIHR Birmingham Biomedical Research Centre (GB)
Good health and well-being
Openalex Percentile: Top 30%
Hepatocellular Carcinoma Treatment and Prognosis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

180P Real-world outcomes of patients with hepatocellular carcinoma receiving first-line atezolizumab with bevacizumab: A UK Midlands cohort — S. Hussain, B. Greef, et al. · Immuno-Oncology Technology (2025) | TGRS Research Map | TGRS